Journal article

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab

NC Tebbutt, F Murphy, D Zannino, K Wilson, MM Cummins, E Abdi, AH Strickland, RM Lowenthal, G Marx, C Karapetis, J Shannon, D Goldstein, SS Nayagam, R Blum, L Chantrill, RJ Simes, TJ Price

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2011

Abstract

BACKGROUND: Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab. PATIENTS AND METHODS: We recorded grade 3, 4, or 5 ATE events and other data (including age, baseline cardiovascular risk factors, history of ATE, and aspirin use) from 471 patients with metastatic colorectal cancer in the MAX (Mitomycin, Avastin, Xeloda) trial of capecitabine monotherapy versus capecitabine with bevacizumab with or without mitomycin C. RESULTS: Bevacizumab-treated patients had 12 grade 3, 4, or 5 ATEs (3.8% incidence). ATEs occurred in 2.1% of patients >65 yea..

View full abstract

University of Melbourne Researchers